Literature DB >> 12430938

Umbilical cord blood for unrelated bone marrow replacement; Asia bank and Japan cord blood bank network update.

Hideo Mugishima1, Tuneo Takahashi, Tokiko Nagamura, Sigetaka Asano, Hidehiko Saito.   

Abstract

Cord blood offers many advantages including a high concentration of hematopoietic stem cells, a large number of potential donors, and ease of harvest. Furthermore, since there is no risk for either the mother or baby, few people refuse to donate. There is thought to be a low risk for virus contamination and also probably a low incidence and severity of GVHD. Cord blood can be obtained quickly without the assistance of a coordinator and one or 2 locus-mismatched HLA is usually acceptable. In Japan, there are 10 cord blood banks supported by the government. Between 1996 and June 2002, 9,500 units were registered with the Japan cord blood bank network (JCBBN). 630 units were delivered and most of these were transplanted. The status of registered cord blood units worldwide is shown. 59,081 units have been registered by NETCORD. The Japan cord blood bank network accounts for 13% of these units. I will discuss the Tokyo cord blood tank (TCBB). The bank at Tokyo, to which we belong, is one of the largest banks in Japan. We helped to establish Asia CORD in 2000 and have held annual conferences and meetings in Tokyo to exchange information. So far, China, Korea, Taiwan, Thailand, Viet Nam and Japan have participated. We accepted three trainees from the Ho Chi Minh City Blood Transfusion and Hematology Center for training in cord blood transplantation in May 2001. In January 2002, a patient with ALL received cord blood and was successfully engrafted at Ho Chi Minh City Blood Transfusion and Hematology Center. We present here the clinical outcome of these patients through Tokyo cord blood bank and Japan cord blood bank network. First, the number of CB units stored and registered at JCBBN and TCBB has increased rapidly over the past two years. Second, the survival rate of acute leukemia patients in release was significantly lower than that in patients in CR. Third, the engraftment rate in patients with metabolic disease (50%) was lower than that in patients with leukemia. Fourth, there was no significant difference in the incidence of acute GVHD greater than grade II between patients with a 1-locus and 2-locus mismatch. Finally, the incidence of acute GVHD was relatively low, and there were no deaths related to acute GVHD.

Entities:  

Mesh:

Year:  2002        PMID: 12430938     DOI: 10.1007/bf03165133

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  5 in total

1.  HLA-DPB1 mismatch induces a graft-versus-leukemia effect without severe acute GVHD after single-unit umbilical cord blood transplantation.

Authors:  T Yabe; F Azuma; K Kashiwase; K Matsumoto; T Orihara; H Yabe; S Kato; K Kato; S Kai; T Mori; S Morishima; M Satake; M Takanashi; K Nakajima; Y Morishima
Journal:  Leukemia       Date:  2017-06-27       Impact factor: 11.528

2.  Successful stem cell transplantation without cryopreservation from a microchimeric haploidentical sibling for refractory acute myeloid leukemia complicated with critical thrombophlebitis and cellulitis.

Authors:  Tsuyoshi Muta; Koji Kato; Testuya Eto; Seido Oku; Ryohei Nawata; Ken Takase; Hideho Henzan; Fumito Arima; Hisashi Gondo; Takashi Okamura; Tsunefumi Shibuya
Journal:  Int J Hematol       Date:  2007-01       Impact factor: 2.490

3.  Unrelated donor marrow transplantation for congenital immunodeficiency and metabolic disease: an update of the experience of the Japan Marrow Donor Program.

Authors:  Naoki Sakata; Keisei Kawa; Koji Kato; Hiromasa Yabe; Miharu Yabe; Masayuki Nagasawa; Hideo Mugishima; Hisato Kigasawa; Masahiro Tsuchida; Yuichi Akiyama; Yasuo Morisima; Yoshihisa Kodera; Shunichi Kato
Journal:  Int J Hematol       Date:  2004-08       Impact factor: 2.490

4.  Umbilical cord blood transplants facilitated by the French cord blood banks network. On behalf of the Agency of Biomedicine, Eurocord and the French society of bone marrow transplant and cell therapy (SFGM-TC).

Authors:  Hanadi Rafii; Federico Garnier; Annalisa Ruggeri; Irina Ionescu; Caroline Ballot; Danièle Bensoussan; Christian Chabannon; Bernard Dazey; John De Vos; Eric Gautier; Christine Giraud; Jérome Larghero; Audrey Cras; Valérie Mialou; Virginie Persoons; Fabienne Pouthier; Jean-Baptiste Thibert; Jean-Hugues Dalle; Gerard Michel; Chantal Kenzey; Fernanda Volt; Vanderson Rocha; Jacques-Olivier Bay; Marie-Thérèse Rubio; Catherine Faucher; Evelyne Marry; Eliane Gluckman
Journal:  Bone Marrow Transplant       Date:  2021-05-14       Impact factor: 5.483

Review 5.  Ethical challenges of cord blood banks: a scoping review.

Authors:  Madjid Soltani Gerdfaramarzi; Shabnam Bazmi; Mehrzad Kiani; Leila Afshar; Mohsen Fadavi; Seyed Ali Enjoo
Journal:  J Med Life       Date:  2022-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.